Drug Trial Radar · NCT07217067
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
Sep 9, 2027
Study completion Sep 9, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
Conditions
- Atrial Fibrillation
Interventions
PKN605Drug
PKN605 is an oral formulation
PlaceboOther
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Atrial fibrillation burden from ECG patch monitorsTime frame: 24 weeks
Locations
40 sites in 7 countries. Site status is shown where the registry gives one.
Cardiology Associates of North MS
Tupelo, Mississippi · Recruiting
Cooper University Hospital
Camden, New Jersey · Recruiting
Weill Cornell Medical Center
New York, New York · Recruiting
Duke Univ Medical Center
Durham, North Carolina · Recruiting
Intermountain Medical Center
Murray, Utah · Recruiting
Swedish Heart and Vascular Clinic
Seattle, Washington · Recruiting
Novartis Investigative Site
Calgary, Alberta, Canada · Recruiting
Novartis Investigative Site
Vancouver, British Columbia, Canada · Recruiting
Novartis Investigative Site
Halifax, Nova Scotia, Canada · Recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada · Recruiting
Novartis Investigative Site
London, Ontario, Canada · Recruiting
Novartis Investigative Site
Newmarket, Ontario, Canada · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Québec, Quebec, Canada · Recruiting
Novartis Investigative Site
Sherbrooke, Quebec, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Xi'an, China · Recruiting
Novartis Investigative Site
Beijing, Beijing Municipality, China · Recruiting
Novartis Investigative Site
Bad Homburg, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Hamburg, Germany · Recruiting
Novartis Investigative Site
Hamburg, Germany · Recruiting
Novartis Investigative Site
Groningen, Netherlands · Recruiting
Novartis Investigative Site
Veldhoven, Netherlands · Recruiting
Novartis Investigative Site
Arnhem, Gelderland, Netherlands · Recruiting
Novartis Investigative Site
Maastricht, Limburg, Netherlands · Recruiting
Novartis Investigative Site
Delft, South Holland, Netherlands · Withdrawn
Novartis Investigative Site
Goes, Zeeland, Netherlands · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Singapore, Singapore, Singapore · Recruiting
Novartis Investigative Site
Liverpool, United Kingdom · Withdrawn
Novartis Investigative Site
London, United Kingdom · Recruiting
Novartis Investigative Site
Brighton, East Sussex, United Kingdom · Recruiting
Novartis Investigative Site
Newcastle upon Tyne, Tyne and Wear, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.